Naringenin Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 297

Clinical Trials

Multiple clinical trials evaluate the biological effects and therapeutic potential of naringenin across diverse health indications, including hepatitis C infection, metabolic syndrome, vascular compliance, bone fractures, and general safety and pharmacokinetics. Predominantly sponsored by academic and medical research institutions such as Massachusetts General Hospital and Pennington Biomedical Research Center, these Phase 1, Early Phase 1, and unclassified phase studies encompass recruitment statuses ranging from completed to active and actively recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06612762	RECRUITING	Bone Fractures	Shahid Beheshti University of Medical Sciences	2024-11-03
NCT05073523	Completed	Healthy	Chalmers University of Technology	2021-09-27	Not Applicable
NCT04697355	COMPLETED	Energy Expenditure; Safety Issues; Glucose Metabolism	Pennington Biomedical Research Center	2021-04-19
NCT04731987	Active not recruiting	Metabolic Syndrome\|Vascular Compliance\|Predisposition to Cardiovascular Disease	University Hospital Clermont-Ferrand\|UMR 1019 Unité de Nutrition Humaine INRAE Auvergne-Rhône Alpes Center\|Department of Beverage Research Chair of analysis and technology of plant-based foods Geisenheim University\|European Fruit Juice Association (AIJN)	2021-02-24	Not Applicable
NCT03582553	COMPLETED	Safety Issues; Pharmacokinetics	Pennington Biomedical Research Center	2018-05-25	EARLY_PHASE1
NCT03582553	Completed	Safety Issues\|Pharmacokinetics	Pennington Biomedical Research Center\|Louisiana Clinical and Translational Science Center	2018-05-25	Early Phase 1
NCT03032861	Completed	Intestinal Diseases	São Paulo State University	2016-09	Not Applicable
NCT02380144	Unknown status	Healthy	University of Hohenheim	2014-01	Not Applicable
NCT01091077	COMPLETED	Hepatitis C Virus; HCV Infection; Chronic HCV; Hepatitis C	Massachusetts General Hospital	2009-06	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-30)

Check the Naringenin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Naringenin binds to cellular oxidative targets and inhibits cytochrome P450 isoforms, particularly CYP1A2, which modulates hepatic xenobiotic metabolism and reduces reactive oxygen species production to prevent oxidative DNA damage. This antioxidant and enzymatic inhibitory activity contributes to anti-inflammatory signaling and altered metabolic pathways, providing potential clinical utility in managing metabolic syndrome, glucose dysregulation, and viral infections such as hepatitis C.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).